GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
D

DOD Biotech PCL DOD.BK · THB

Consumer Staples · SET · 🇹🇭 Thailand

Compare

0.62

0.00%

Close of 9 Nov 2026, in THB

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About DOD Biotech PCL

Its shares trade on SET under the ticker DOD.BK. It has been listed since 20 June 2018. In the fiscal year to 31 December 2025, it reported revenue of THB 609.0m and net income of THB 59.6m. At that date it held total assets of THB 1.15bn and shareholders' equity of THB 958.3m.

DOD Biotech Public Co., Ltd. is engaged in manufacture of food supplements. The company is headquartered in Samut Sakhon, Samut Sakhon. The company went IPO on 2018-06-20. The firm offers one-stop service, including production consultations, formula development, food serial number registration with the Food and Drug Administration (FDA), as well as product manufacture. The firm also produces food supplements under its own trademark, namely protein supplements under the brand Dai a to. Its two operating business segments consist of beauty supplement segment and health supplement segment, which includes dietary supplement for digestive system, protein supplements and brain supplements. The products come in the forms of hard capsules, tablets and powder. The company’s headquarter is located in Samut Sakhon.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
Consumer Staples
Industry
Personal Products
Listed since
20 Jun 2018
Employees
286

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • DOD Biotech PCL possesses several strengths that contribute to its success:

Weaknesses

  • Despite its strengths, DOD Biotech PCL also faces certain weaknesses:

Opportunities

  • DOD Biotech PCL can leverage various opportunities to further expand its business:

Threats

  • Several external factors pose threats to DOD Biotech PCL:

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.